Inhibikase Therapeutics Files 8-K Report
Ticker: IKT · Form: 8-K · Filed: Jan 29, 2025 · CIK: 1750149
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: IKT
TL;DR
IKT filed an 8-K on Jan 29, 2025. Details TBD.
AI Summary
On January 29, 2025, Inhibikase Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or financial figures within the provided text. The company is incorporated in Delaware and headquartered in Atlanta, Georgia.
Why It Matters
This filing indicates a regulatory update from Inhibikase Therapeutics, Inc., which may contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific financial or operational details that would indicate high risk.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- January 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Atlanta, Georgia (location) — Address of Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing is categorized under 'Other Events' and the provided text does not specify the exact event.
When was this 8-K report filed?
The report was filed on January 29, 2025.
What is the principal business address of Inhibikase Therapeutics, Inc.?
The principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339.
What is the company's telephone number?
The company's telephone number is (678) 392-3419.
What is the SIC code for Inhibikase Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836 for Biological Products (No Diagnostic Substances).
Filing Stats: 921 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2025-01-29 16:05:22
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
Filing Documents
- d919757d8k.htm (8-K) — 30KB
- 0001193125-25-015648.txt ( ) — 154KB
- ikt-20250129.xsd (EX-101.SCH) — 3KB
- ikt-20250129_lab.xml (EX-101.LAB) — 18KB
- ikt-20250129_pre.xml (EX-101.PRE) — 11KB
- d919757d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words "expect," "will," and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities, or future events or conditions, including its ability to consider and identify strategic options for the risvodetinib program. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the Company's ability to commence and execute a Phase 2b 702' trial to evaluate IkT-001Pro as a treatment for PAH, as well as those risks discussed in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 29, 2025 INHIBIKASE THERAPEUTICS, INC. By: /s/ Milton H. Werner, Ph.D. Milton H. Werner, Ph.D. President and Chief Executive Officer